The phase 1 first-in-human study is designed to assess the safety, tolerability & preliminary clinical activity of 177Lu-RAD202 in individuals with HER2-positive metastatic solid tumours. The ...
Radiopharm Theranostics Ltd. has been granted Belberry Human Research Ethics Committee (HREC) approval in Australia to initiate a first-in-human phase I therapeutic study of 177Lu-labeled RAD-202 ...